Kolltan Pharmaceuticals Inc. Enters into License and Option Agreement With MedImmune

Published: Jul 29, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which Kolltan will in-license a monoclonal antibody targeting the Her3 receptor tyrosine kinase from MedImmune. Based on the current program status, Kolltan anticipates initiating Phase 1 clinical testing of this product in the first quarter of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news